Non-Small Cell Lung Cancer
Conditions
Interventions
Case series:PDX model establishment with tumor and MiniPDX drug sensitive test after the PDX model is established
Sponsors
Cancer Hospital Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-75 years old; 2. Patients with NSCLC confirmed by histopathology or cytology; 3. The damage caused by other treatment has been recovered; 4. Patients who can take biopsy to obtain fresh tumor tissue samples; 5. CT / MRI can be used to evaluate the curative effect of patients with objective tumor focus meeting the criteria of RECIST 1.1; 6. Patients with KPS score >=60 and expected survival time >=3 months; 7. The subjects participated voluntarily, signed the informed consent, had good compliance, and could actively treat and cooperate with the follow-up.
Exclusion criteria
Exclusion criteria: 1. The general condition of the patients is poor, and it is estimated that they can not tolerate surgery and postoperative chemotherapy; 2. Patients with distant blood metastasis, unstable angina pectoris, symptomatic congestive heart failure, severe arrhythmia, myocardial infarction in the past 6 months, and prolonged QT interval (> 450ms); 3. The patient cannot be followed up or is participating in other clinical trials; 4. Patients with drug abuse; or any medical, psychological or social condition that may affect the study, unstable compliance of patients, or even endanger the safety of patients; 5. patients who were treated with other experimental drugs outside the trial within 4 weeks before the start of the study, or participated in another clinical study that had an impact on the results of the study at the same time; 6. Patients who are unable or unwilling to sign informed consent due to mental or medical instability; 7. According to the comprehensive evaluation, the researchers think it is not suitable for the patients participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Progress-Free Survival; | — |
Countries
China
Contacts
Public ContactLi Ning
Cancer Hospital of Chinese Academy of Medical Sciences
Outcome results
None listed